Timothy Patrick Lynch
Director of Investments bei Stonepine Capital Management LLC
Vermögen: 290 751 $ am 31.05.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jon Mabrey Plexico | M | 55 |
Stonepine Capital Management LLC
Stonepine Capital Management LLC Investment ManagersFinance Stonepine Capital Management LLC (Stonepine) is an independent registered investment advisor and hedge fund manager headquartered in Bend, Oregon. The firm was founded by Jon M. Plexico in 2006. Stonepine serves as the general partner and investment adviser to a private investment fund. | 18 Jahre |
Jeffrey R. Latts | M | 76 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 17 Jahre |
Marianne T. Armstrong | M | 69 | 22 Jahre | |
Michael E. Schick | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 15 Jahre |
Kenny Storch | M | - |
Stonepine Capital Management LLC
Stonepine Capital Management LLC Investment ManagersFinance Stonepine Capital Management LLC (Stonepine) is an independent registered investment advisor and hedge fund manager headquartered in Bend, Oregon. The firm was founded by Jon M. Plexico in 2006. Stonepine serves as the general partner and investment adviser to a private investment fund. | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Stephen N. Rosenfield | M | 74 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 9 Jahre |
Nancy E. Pecota | F | 64 | 10 Jahre | |
Paul Berns | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 Jahre |
Jeffrey M. Nugent | M | 76 |
BioForm Medical, Inc.
BioForm Medical, Inc. Medical SpecialtiesHealth Technology BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA. | 1 Jahre |
Jordan I. Siegel | M | 58 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 2 Jahre |
Ann Hanham | M | 71 | 2 Jahre | |
Michael E. Hart | M | - |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 5 Jahre |
Frederick Lwee | M | 43 |
BioForm Medical, Inc.
BioForm Medical, Inc. Medical SpecialtiesHealth Technology BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA. | - |
Thomas McLain | M | 66 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 9 Jahre |
Peter B. Davis | M | 77 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 6 Jahre |
Jonathan Leff | M | 55 | 12 Jahre | |
Timothy M. Ruane | M | 59 | - | |
James Healy | M | 59 | 15 Jahre | |
Mark L. Smith | M | 72 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 7 Jahre |
Rick Anderson | M | 63 | 3 Jahre | |
Adam Logal | M | 46 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 5 Jahre |
David Stout | M | 70 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 Jahre |
Tamar Howson | F | 75 | 9 Jahre | |
Jason Aryeh | M | 55 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 6 Jahre |
N. C. Joseph Lai | M | 82 |
BioForm Medical, Inc.
BioForm Medical, Inc. Medical SpecialtiesHealth Technology BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA. | 11 Jahre |
Richard B. Love | M | 62 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 7 Jahre |
Nishan de Silva | M | 51 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 Jahre |
Deno G. Bokas | M | 61 | 1 Jahre | |
Sandra C. Heine | F | 62 | 11 Jahre | |
Brian Levy | M | 72 | 4 Jahre | |
Howard Moore | M | - |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | - |
Matthew Kalnik | M | 61 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 5 Jahre |
Freddie K. Park | F | - |
BioForm Medical, Inc.
BioForm Medical, Inc. Medical SpecialtiesHealth Technology BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA. | - |
Craig Tooman | M | 58 | 4 Jahre | |
Adam D. Gridley | M | 52 |
BioForm Medical, Inc.
BioForm Medical, Inc. Medical SpecialtiesHealth Technology BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA. | - |
Gregory Flesher | M | 54 | 4 Jahre | |
Kevin Sidow | M | - |
BioForm Medical, Inc.
BioForm Medical, Inc. Medical SpecialtiesHealth Technology BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA. | 3 Jahre |
Jeremy Bender | M | 52 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 Jahre |
Michael E. Markels | M | - | 1 Jahre | |
Mark G. Edwards | M | 66 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 Jahre |
Steven Fruchtman | M | 73 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 2 Jahre |
Marianne A. Porter | M | 69 | 10 Jahre | |
Bruce Goldsmith | M | 58 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 4 Jahre |
Nathan Michael LiaBraaten | M | - |
Stonepine Capital Management LLC
Stonepine Capital Management LLC Investment ManagersFinance Stonepine Capital Management LLC (Stonepine) is an independent registered investment advisor and hedge fund manager headquartered in Bend, Oregon. The firm was founded by Jon M. Plexico in 2006. Stonepine serves as the general partner and investment adviser to a private investment fund. | - |
Charles Q. Morris | M | 59 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 2 Jahre |
Evan S. Melrose | M | 54 |
BioForm Medical, Inc.
BioForm Medical, Inc. Medical SpecialtiesHealth Technology BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA. | 9 Jahre |
Jim Shaffer | M | 57 | 3 Jahre | |
Kerry Clem | M | 54 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 Jahre |
Martin Zugel | M | - |
BioForm Medical, Inc.
BioForm Medical, Inc. Medical SpecialtiesHealth Technology BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA. | - |
Curtis L. Ruegg | M | 61 | 2 Jahre | |
Barbara E. Baring | F | - |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 Jahre |
Thomas E. Rathjen | M | - |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | - |
Christopher John Wesley Dennis | M | 65 |
BioForm Medical, Inc.
BioForm Medical, Inc. Medical SpecialtiesHealth Technology BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA. | 2 Jahre |
Francis Chen | M | 75 | 1 Jahre | |
Patricia Altavilla | F | 66 |
BioForm Medical, Inc.
BioForm Medical, Inc. Medical SpecialtiesHealth Technology BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA. | 3 Jahre |
Peter van Vlasselaer | M | 64 | 5 Jahre | |
David Happel | M | 62 | 2 Jahre | |
Michael S. Eison | M | - | - | |
Sunil Patel | M | 52 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 Jahre |
Sylvia Kamenski | F | 71 |
BioForm Medical, Inc.
BioForm Medical, Inc. Medical SpecialtiesHealth Technology BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA. | - |
Stephen G. Sudovar | M | 77 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 8 Jahre |
William Halter | M | 63 | 4 Jahre | |
Steven Bryant Porter | M | 66 | 11 Jahre | |
Jeffrey Mark Wells | M | - |
BioForm Medical, Inc.
BioForm Medical, Inc. Medical SpecialtiesHealth Technology BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA. | - |
Jason Shelton | M | - |
BioForm Medical, Inc.
BioForm Medical, Inc. Medical SpecialtiesHealth Technology BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA. | 3 Jahre |
Luke Seikkula | M | 60 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 Jahre |
Christopher Rivera | M | 63 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 1 Jahre |
Thorsten von Stein | M | 62 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 9 Jahre |
Norman L. Halleen | M | 70 | 9 Jahre | |
Williamson Z. Bradford | M | 62 | - | |
Susan Wong | F | 61 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 10 Jahre |
Michael D. Casey | M | 78 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 Jahre |
Andrew Grethlein | M | 59 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 5 Jahre |
Bruce K. Bennett | M | 73 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 4 Jahre |
David A. DeLong | M | - |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 5 Jahre |
Mitchell H. Friedlaender | M | 78 | 12 Jahre | |
Pablo Cagnoni | M | 60 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 2 Jahre |
Derek A. Bertocci | M | 70 |
BioForm Medical, Inc.
BioForm Medical, Inc. Medical SpecialtiesHealth Technology BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA. | 2 Jahre |
Dennis Condon | M | 75 |
BioForm Medical, Inc.
BioForm Medical, Inc. Medical SpecialtiesHealth Technology BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA. | - |
Jon Saxe | M | 88 | 16 Jahre | |
Karin Eastham | F | 74 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 5 Jahre |
David Mahoney | M | 69 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 4 Jahre |
Linda S. Jenckes | F | 76 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 13 Jahre |
James Caruso | M | 65 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 4 Jahre |
Thomas Wiggans | M | 72 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 1 Jahre |
William Ringo | M | 78 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 Jahre |
Stephen Jaeger | M | 79 | 5 Jahre | |
George W. Ebright | M | 85 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | - |
Lawrence Blatt | M | 62 | 6 Jahre | |
Anders Paul Wiklund | M | 84 | 12 Jahre | |
James Pennington | M | 81 | 3 Jahre | |
Mark Leschly | M | 55 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 5 Jahre |
Stewart John Hen | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 5 Jahre |
Thomas H. Silberg | M | 76 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 1 Jahre |
Babatunde Otulana | M | 67 | 11 Jahre | |
David F. Heniges | M | 80 | 7 Jahre | |
Marvin E. Jaffe | M | 87 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 12 Jahre |
Steven Basta | M | 59 |
BioForm Medical, Inc.
BioForm Medical, Inc. Medical SpecialtiesHealth Technology BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA. | 8 Jahre |
W. Scott Harkonen | M | - | 4 Jahre | |
Antonis Koutsoukos | M | - |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Timothy Patrick Lynch
- Persönliches Netzwerk